Free · no account · quoted from the filing

What changed in MRK's 10-Q

Source: 10-Q filed 2026-05-04 · compared against 10-Q 2025-11-05. Every passage below is quoted verbatim from the filing itself.

Acquisitions

This filing

acquired Cidara Therapeutics, Inc. ... for $9.2 billion

Liquidity

This filing

Cash and investments $ 6,807 $ 15,521

Dividends

This filing

declared a quarterly dividend of $0.85 per share

Legal - Keytruda

This filing

the PTAB issued Final Written Decisions finding all challenged claims of the nine patents unpatentable

Legal - Januvia/Janumet

This filing

the Tokyo District Court orally indicated its view that the extended patent covers Sawai’s tablets

Cash Flow

This filing

Cash provided by operating activities was $3.9 billion in the first three months of 2026 compared with $2.5 billion in the first three months of 2025

Share Repurchases

This filing

During the first three months of 2026, the Company purchased $874 million ... of its common stock for its treasury

What it means — the analyst reading

The passages above are the company's own words. The plain-English reading of them — what changed, why it matters, and the direction of travel — is part of the Filing Change Monitor.

See the Filing Change Monitor →

Compared from narrative excerpts (outlook, risks, MD&A) of both filings — quotes are verbatim from the new filing. Not advice. Source: company SEC filings via stockportfolio.pro. Educational, not investment advice.